1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Lewy body Dementia-Pipeline Insights, 2017

Lewy body Dementia-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Lewy body Dementia-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Lewy body Dementia. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Lewy body Dementia. DelveInsight’s Report also assesses the Lewy body Dementia therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Lewy body Dementia
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Lewy body Dementia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Lewy body Dementia and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Lewy body Dementia-Pipeline Insights, 2017
Illustrative

- Lewy body Dementia Overview
- Lewy body Dementia Pipeline Therapeutics
- Lewy body Dementia Therapeutics under Development by Companies
- Lewy body Dementia Filed and Phase III Products
- Comparative Analysis
- Lewy body Dementia Phase II Products
- Comparative Analysis
- Lewy body Dementia Phase I and IND Filed Products
- Comparative Analysis
- Lewy body Dementia Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Lewy body Dementia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Lewy body Dementia - Discontinued Products
- Lewy body Dementia - Dormant Products
- Companies Involved in Therapeutics Development for Lewy body Dementia
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Lewy body Dementia, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Lewy body Dementia Assessment by Monotherapy Products
- Lewy body Dementia Assessment by Combination Products
- Lewy body Dementia Assessment by Route of Administration
- Lewy body Dementia Assessment by Stage and Route of Administration
- Lewy body Dementia Assessment by Molecule Type
- Lewy body Dementia Assessment by Stage and Molecule Type
- Lewy body Dementia Therapeutics - Discontinued Products
- Lewy body Dementia Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Lewy body Dementia, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Lewy body Dementia Assessment by Monotherapy Products
- Lewy body Dementia Assessment by Combination Products
- Lewy body Dementia Assessment by Route of Administration
- Lewy body Dementia Assessment by Stage and Route of Administration
- Lewy body Dementia Assessment by Molecule Type
- Lewy body Dementia Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Proteomics Market by Instrument, Reagent & Service, Application - Forecast to 2021

Proteomics Market by Instrument, Reagent & Service, Application - Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global proteomics market is projected to reach USD 21.87 billion by 2021, at a CAGR of 11.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising acceptance ...

Global Market Study on High Content Screening: Pharmaceutical and Healthcare Segment to Remain Dominant Through 2025

Global Market Study on High Content Screening: Pharmaceutical and Healthcare Segment to Remain Dominant Through 2025

  • $ 4900
  • Industry report
  • December 2016
  • by Persistence Market Research

This report by Persistence Market Research on the global high content screening market for the period 2016–2025 presents an outlook of the market across the globe. The primary objective of the report ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.